【摘要】 目的观察注射用头孢曲松钠-舒巴坦钠治疗成人社区获得性细菌性下呼吸道感染的临床有效性、安全性。方法中度、重度细菌性下呼吸道感染病人186例,随机分为2组,注射用头孢曲松钠-舒巴坦钠组96例。男59例,女37例;年龄(48±13)岁。予注射用头孢曲松钠-舒巴坦钠1.25g静脉注射,2次/d;注射用青霉素钠组90例。男56例,女34例;年龄(48±12)岁。予注射用青霉素钠480万u静脉注射,2次/d。2组均以7～10d为1个疗程。结果注射用头孢曲松钠)舒巴坦钠组与注射用青霉素钠组的临床有效率分别为89.6%与66.7%(P<0.05),2组无明显不良反应。结论注射用头孢曲松钠-舒巴坦钠是治疗中度、重度细菌性下呼吸道感染安全﹑有效的抗生素。更多还原

【Abstract】 Objective To observe the clinical effect and safety of the th erapy of Ceftriaxone Sodium and Sulbactam for Injection (CSSI) on obtainable and bacterial Lower Respiratory Tract Infection (LRTI) in Adult Society. Methods 186 mid-level or severe bacterial LRTI cases were randomly divided into two g roups. 96 patients (59 males, 37 females, between the age of 35 and 61) took 1.2 5 g CSSI with intravenous injection twice a day. 90 patients (56 males, 34 femal es, between the age of 36 and 60) took 4.8 million units of Benzyl Penicillin So dium for Injection (BPSI) twice a day. Both of the treatments were sustained for 7 to 10 days. Results The effective clinical rate of CSSI and BPSI were 89. 6% and 66.7% respectively (P <0.05). None of these two groups brought about unde sirable reaction. Conclusion CSSI is a safe and effective antibiotic for the therapy of mid-level and severe LRTI.更多还原